[A phase II study of carboplatin to bronchogenic carcinoma of the lung. Carboplatin Cooperative Study Group for Lung Carcinoma].
A Phase II study of carboplatin, an analog of cisplatin, was performed in patients with primary lung cancer at 17 institutions throughout Japan. Carboplatin was administered intravenously by two dosing schedules at 300 mg/m2 and 400 mg/m2. Out of 138 patients entered in the study, 101 were judged eligible for evaluation by the extramural Review Committee, and the overall response rate was 15.8% (16/101). The response rate for small-cell lung carcinoma was 25.5% (13/51) and for non-small cell lung carcinoma was 6.0% (3/50). Carboplatin was found to be effective for small-cell lung carcinoma. As for hematological toxicities, thrombocytopenia (less than 7 X 10(4)/mm3) and leukopenia (less than 3,000/mm3) were observed in 46.5% and 43.6% of cases, respectively. Nausea/vomiting was the main symptomatic side effect and was observed at an incidence of 42.6%. There was no renal, oto-or, neurotoxicities observed.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016190:Carboplatin; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D009944:Organoplatinum Compounds; D016190:Carboplatin